In previous NGS genomic profiling studies of HER2+ breast cancer patients, fusion events are common, with ERBB2 being the most frequently involved gene (Chen et al., 2020) with the most frequent co-mutations found in TP53 (Schubert et al., 2023; Wang T. et al., 2022). Here, TP53 is linked to breast carcinoma.